Picture of Advanced Oncotherapy logo

AVO — Advanced Oncotherapy News Story

gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

RCS - Advanced Oncotherapy - Video showcases progress on LIGHT system process

For best results when printing this announcement, please click on link below:

RNS Number : 4505J  Advanced Oncotherapy PLC  27 April 2022


Reach non-regulatory announcement


27 April 2022




("Advanced Oncotherapy" or the "Company")


Launch of a video showcasing progress on LIGHT system process


Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, today announces the launch of a
video showcasing progress on the LIGHT system infrastructure and set-up at its
assembly and integration site located in Daresbury, Cheshire.


As outlined in the operational update released by the Company on 26 April
2022, it has made good progress along its timescale of summer 2022 for having
a fully operational LIGHT system operating at 230 MeV.


·   Finalised building rooms for the infrastructure required to
accommodate the LIGHT machine and its ancillary equipment, which have more
than 34,000 components.


·   The LIGHT machine assembly is on track. To date, 20 of the 21
accelerating modules needed to accelerate protons to an energy of 230 MeV have
been radio-frequency (RF) conditioned and the control systems are in place.


·    Patient treatment will take place in the treatment room which is
located at the end of the accelerator where a state-of-the-art robot chair,
with CT scanner and X-Ray panels for accurate patient positioning, has been


The video launched today, and which is available on the Company's website
(https://www.avoplc.com/en-gb/Company/Assembly-Verification-Validation) ,
showcases the various complex elements at play in the integration of the
Company's LIGHT system:


Further details on the specificities of the machine, its control systems and
the patient treatment facility, which are highlighted in the video, are
detailed below:


·      The accelerator, currently under assembly, is powered by:


o  13 klystrons, which provide high radio-frequency power to the machine to
accelerate the proton beam, operating at 3 GHz, inducing an electromagnetic
field inside the LIGHT accelerating modules that is oscillating at a frequency
of three billion times per second.


o  Four inductive output tubes (IOTs), operating at 750 MHz which generate
the relevant power for the radiofrequency quadrupole (RFQ).


·     The accelerator is cooled, kept under vacuum and monitored by beam
diagnostics and the Company's time-of-flight energy measurement algorithm.


·     The proprietary LIGHT Accelerator Control System integrates more
than 300 different devices and is driven by operators in the control room:


o  The Company and its partners have developed c.250 front end control
software instances to accelerate, steer and monitor the proton beam.


o  The measuring systems calculate the speed of protons in picosecond, the
time it takes light to travel one third of a millimetre.


o  20 Gb of nominal data is transferred per day to support the beam
optimisation and control.


·    Protons go through a gallery of accelerators moving as a 200 Hz
pulsed beam through the RFQ, the SCDTLs and then through the 15 CCLs
accelerating up to a maximum of 230 MeV.


o  These accelerating structures have been aligned and pre-aligned, requiring
fine adjustment devices to position components such as the Permanent Magnet
Quadrupoles, which are used to focus the proton beam, to a position accuracy
of 50 μm, the average diameter of human hair being 75 μm.


·   LIGHT is the first proton therapy system integrated with a dedicated
vertical CT scanner. The diagnostic CT scanner, which weighs over 2,000 kg and
can be moved with sub-millimetre accuracy, has been mounted vertically to aid
patient comfort during treatment.


- ENDS -



 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Liz Kirchner (Corporate Finance)           Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000



·    Inductive output tubes (IOT) - IOTs are high power radio-frequency
generators used to bring the relevant power to the RFQ.


·      Radio-frequency quadrupole (RFQ) - The RFQ is a copper
accelerating structure which focuses, bunches and accelerates protons up to
5MeV. The RFQ sits between the proton source and the side-coupled drift tube


·    Side-coupled drift tube linacs (SCDTLs) - The LIGHT accelerator
includes four SCDTL modules which accelerate protons from 5MeV to 37.5MeV. The
SCDTLs sit between the RFQ and the CCLs.


·      Coupled cavity linacs (CCLs) - The CCL structures or "higher
speed accelerators" are an essential part of the LIGHT Accelerator. They
consist of a series of "cells" which accelerate the protons from 37.5MeV to
energies that can be applied usefully to a clinical setting (70MeV to 230MeV).


·      Klystrons - The Klystrons provide high radio-frequency power to
the machine to accelerate the proton beam.


·     Permanent magnet quadrupoles (PMQs) - The PMQs are used to focus
and align the proton beam. They are placed along the LIGHT accelerator within
the SCDTLs and CCLs (in between acceleration tanks) and also in the medium
energy beam transfer line.


·    RF conditioning - The radio-frequency (RF) conditioning involves
gradually increasing the input power until there is an electrical "breakdown".
After each breakdown, the accelerating modules can sustain an increase in the
input power. This process is continued and iterative until the power reached
is 20% above the nominal values. This ensures great stability when operating
at nominal power. As the Daresbury LIGHT system is expected to be the first
linear proton accelerator to be commissioned for medical use, the RF
conditioning is unprecedented, hence carrying some level of uncertainty with
regards to the time needed to complete this important task. This risk has been
significantly removed following recent progress.


About Advanced Oncotherapy Plc


Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.


Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.


Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.


About Reach announcements


This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)

Recent news on Advanced Oncotherapy

See all news